Matches in Wikidata for { <http://www.wikidata.org/entity/Q94141158> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q94141158 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q94141158 description "wetenschappelijk artikel" @default.
- Q94141158 description "наукова стаття, опублікована в жовтні 2019" @default.
- Q94141158 name "LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)" @default.
- Q94141158 name "LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)" @default.
- Q94141158 type Item @default.
- Q94141158 label "LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)" @default.
- Q94141158 label "LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)" @default.
- Q94141158 prefLabel "LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)" @default.
- Q94141158 prefLabel "LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)" @default.
- Q94141158 P1433 Q94141158-F1478865-F460-45F9-B863-C92622198471 @default.
- Q94141158 P1476 Q94141158-651B6491-7C6C-442A-8305-A7A7A74F3209 @default.
- Q94141158 P2093 Q94141158-132DCAF6-C8B2-45EC-A703-CA3548B73F5D @default.
- Q94141158 P2093 Q94141158-22446702-FC51-4FF6-9442-760E7D98C85E @default.
- Q94141158 P2093 Q94141158-2FAE6FC8-36EB-4587-8E0E-AD61F956BE5B @default.
- Q94141158 P2093 Q94141158-36F746F9-0097-4BF8-808E-F84FC5CB9489 @default.
- Q94141158 P2093 Q94141158-3C6DA27F-907A-4AA2-B061-842A3822B2EB @default.
- Q94141158 P2093 Q94141158-5BCFBBBC-16C5-4118-928C-B01639B9EF92 @default.
- Q94141158 P2093 Q94141158-605CC734-7B9A-4A22-95B7-FD319692FA2D @default.
- Q94141158 P2093 Q94141158-7E6C3DEF-804E-4A63-B391-5FF926A4C240 @default.
- Q94141158 P2093 Q94141158-9E08596D-5FF7-4BFA-ADB3-3BC2750A87C4 @default.
- Q94141158 P2093 Q94141158-A05B0FD3-D366-478D-A8B6-93EE5A5380DC @default.
- Q94141158 P2093 Q94141158-EAD4B71C-E76A-4CB1-8CE6-337339FCEBC1 @default.
- Q94141158 P2093 Q94141158-F89D3926-5438-4B8C-A6D6-C2032FC4406B @default.
- Q94141158 P275 Q94141158-5660c50c-34b5-4c1e-ae83-9806b346111a @default.
- Q94141158 P304 Q94141158-866CCD8F-BA4C-43DF-9F9A-4CE81B65794B @default.
- Q94141158 P31 Q94141158-994ADA83-281E-4790-A036-90AFEC93895D @default.
- Q94141158 P356 Q94141158-8A4A503A-D208-420D-9132-CEE75A7A65B6 @default.
- Q94141158 P433 Q94141158-47C1F5F5-87A6-47D1-BD07-F1BB30C78BC2 @default.
- Q94141158 P478 Q94141158-7E1D87C7-C119-4E1D-A64B-232311FFA9A1 @default.
- Q94141158 P50 Q94141158-43A34DDF-C3C1-40E4-97F2-9389D65DDBC2 @default.
- Q94141158 P577 Q94141158-323BFBDD-DB30-4A01-9D60-CB36DC2C9183 @default.
- Q94141158 P6216 Q94141158-41db1f25-aa94-47c4-9d8c-d2a8589776c5 @default.
- Q94141158 P921 Q94141158-b68aa629-4b19-8317-9896-18720216b22c @default.
- Q94141158 P932 Q94141158-30C01B47-C77E-4EA3-8895-3073DA5631A8 @default.
- Q94141158 P356 OFZ415.2496 @default.
- Q94141158 P1433 Q27725953 @default.
- Q94141158 P1476 "LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)" @default.
- Q94141158 P2093 "Bebi Yassin-Rajkumar" @default.
- Q94141158 P2093 "Bruce Smith" @default.
- Q94141158 P2093 "Dave Anderson" @default.
- Q94141158 P2093 "Geert Leroux-Roels" @default.
- Q94141158 P2093 "Isabel Leroux-Roels" @default.
- Q94141158 P2093 "Joanne M Langley" @default.
- Q94141158 P2093 "Johanna Spaans" @default.
- Q94141158 P2093 "Nathalie Machluf" @default.
- Q94141158 P2093 "Pierre van Damme" @default.
- Q94141158 P2093 "Timo Vesikari" @default.
- Q94141158 P2093 "Vlad Popovic" @default.
- Q94141158 P275 Q24082749 @default.
- Q94141158 P304 "S998-S998" @default.
- Q94141158 P31 Q13442814 @default.
- Q94141158 P356 "10.1093/OFID/OFZ415.2496" @default.
- Q94141158 P433 "Suppl 2" @default.
- Q94141158 P478 "6" @default.
- Q94141158 P50 Q113303180 @default.
- Q94141158 P577 "2019-10-23T00:00:00Z" @default.
- Q94141158 P6216 Q50423863 @default.
- Q94141158 P921 Q117749 @default.
- Q94141158 P932 "6810620" @default.